Heparin during endovascular stroke treatment seems safe.


Journal

Journal of neuroradiology = Journal de neuroradiologie
ISSN: 0150-9861
Titre abrégé: J Neuroradiol
Pays: France
ID NLM: 7705086

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 05 10 2018
revised: 11 01 2019
accepted: 29 01 2019
pubmed: 18 2 2019
medline: 16 4 2020
entrez: 18 2 2019
Statut: ppublish

Résumé

the effect of intravenous heparin during mechanical thrombectomy for acute ischemic stroke is not clear. We aimed to study efficacy and safety of heparin use during endovascular stroke treatment in a real-world setting. patients with anterior circulation stroke were divided, based on the use of intraprocedural heparin, in those treated and those untreated. Main outcomes were successful reperfusion defined as a TICI Score ≥ 2b, 3-month functional independence defined as a modified Rankin Scale ≤ 2, symptomatic intracranial hemorrhage (sICH) and mortality. 361 patients were eligible for analysis; 200 were (H+) and 161 (H-). The (H-) group showed higher age and ASPECTS (74 ± 14 vs. 68.9 ± 12.2; P = 0.001; 8 ± 1.6 vs. 7.4 ± 2.1; P = 0.009) without differences in vascular risk factors. Heparin untreated patients showed a shorter onset-to-reperfusion time (271 ± 57.6 min vs. 309 ± 102.2 min; P < 0.001). No differences were found in 3-month functional independence, sICH and mortality whereas the rate of successful reperfusion was higher in the (H-) group. After logistic regression analysis successful reperfusion was independently associated with CT ASPECTS (OR: 1.16; 95%CI 1.01-1.35; P = 0.040) but inversely associated with the use of heparin (OR: 0.48; 95% CI 0.24-0.98; P = 0.045). Heparin use during mechanical thrombectomy for anterior circulation acute ischemic stroke in a real world setting is safe.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
the effect of intravenous heparin during mechanical thrombectomy for acute ischemic stroke is not clear. We aimed to study efficacy and safety of heparin use during endovascular stroke treatment in a real-world setting.
MATERIALS AND METHODS METHODS
patients with anterior circulation stroke were divided, based on the use of intraprocedural heparin, in those treated and those untreated. Main outcomes were successful reperfusion defined as a TICI Score ≥ 2b, 3-month functional independence defined as a modified Rankin Scale ≤ 2, symptomatic intracranial hemorrhage (sICH) and mortality.
RESULTS RESULTS
361 patients were eligible for analysis; 200 were (H+) and 161 (H-). The (H-) group showed higher age and ASPECTS (74 ± 14 vs. 68.9 ± 12.2; P = 0.001; 8 ± 1.6 vs. 7.4 ± 2.1; P = 0.009) without differences in vascular risk factors. Heparin untreated patients showed a shorter onset-to-reperfusion time (271 ± 57.6 min vs. 309 ± 102.2 min; P < 0.001). No differences were found in 3-month functional independence, sICH and mortality whereas the rate of successful reperfusion was higher in the (H-) group. After logistic regression analysis successful reperfusion was independently associated with CT ASPECTS (OR: 1.16; 95%CI 1.01-1.35; P = 0.040) but inversely associated with the use of heparin (OR: 0.48; 95% CI 0.24-0.98; P = 0.045).
CONCLUSIONS CONCLUSIONS
Heparin use during mechanical thrombectomy for anterior circulation acute ischemic stroke in a real world setting is safe.

Identifiants

pubmed: 30772368
pii: S0150-9861(18)30373-0
doi: 10.1016/j.neurad.2019.01.095
pii:
doi:

Substances chimiques

Anticoagulants 0
Heparin 9005-49-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

373-377

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Fabrizio Sallustio (F)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy; Neurorehabilitation Unit, Santa Lucia Foundation, via Ardeatina 306/354, 00142, Rome, Italy. Electronic address: fsall75@gmail.com.

Caterina Motta (C)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy; Neurorehabilitation Unit, Santa Lucia Foundation, via Ardeatina 306/354, 00142, Rome, Italy. Electronic address: caterinamotta86@hotmail.it.

Stefano Merolla (S)

Interventional Radiology and Neuroradiology, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: stefanomerolla@yahoo.it.

Giacomo Koch (G)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy; Neurorehabilitation Unit, Santa Lucia Foundation, via Ardeatina 306/354, 00142, Rome, Italy. Electronic address: giakoch@gmail.com.

Francesco Mori (F)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: mrofnc01@uniroma2.it.

Fana Alemseged (F)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: fanalemseged@gmail.com.

Daniele Morosetti (D)

Interventional Radiology and Neuroradiology, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: danielemorosetti@hotmail.com.

Valerio Da Ros (V)

Interventional Radiology and Neuroradiology, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: valeriodaros@hotmail.com.

Roberto Gandini (R)

Interventional Radiology and Neuroradiology, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: roberto.gandini@fastwebnet.it.

Marina Diomedi (M)

Comprehensive Stroke Center, Department of Systems Medicine, University of Tor Vergata, viale Oxford 81, 00133, Rome, Italy. Electronic address: marina.diomedi@uniroma2.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH